三生國健(688336.SH):SSGJ-617注射液晚期實體瘤臨牀試驗獲批
格隆匯3月22日丨三生國健(688336.SH)公佈,近日,三生國健藥業(上海)股份有限公司SSGJ-617注射液收到國家藥品監督管理局核准簽發的晚期實體瘤臨牀試驗《藥物臨牀試驗批准通知書》,並將於近期開展I期臨牀試驗。
SSGJ-617是國內首款以PSGL-1為靶標的拮抗型抗體,可誘導M2樣巨噬細胞功能重編後轉換為M1樣表型,進而產生抗腫瘤的促炎性免疫應答。
PSGL-1(P-選凝素糖蛋白配基-1)是一種粘附分子,參與響應組織損傷或炎症的免疫細胞運送。巨噬細胞可以響應其微環境中的信號而發揮不同的功能作用,包括指導促炎性和抗炎性免疫反應的能力。SSGJ-617單克隆抗體可高親和力的結合PSGL-1,引起巨噬細胞重編程,誘導腫瘤微環境激活T細胞和其他免疫細胞募集,對腫瘤進行協同免疫攻擊。與目前的PD-1療法相比,SSGJ-617抗體能表現出更大的促炎症反應,刺激免疫應答。
SSGJ-617最初由Verseau Therapeutics研發,三生國健獲得其大中華區權益。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.